OPTIMISING TREATMENT WITH ELAPRASE®

All information in this infographic is taken from the ELAPRASE® Summary of Product Characteristics

WEIGHT-BASED DOSING

ELAPRASE® is dosed according to the weight of the patient with Hunter syndrome. The weight-based dose for children and adolescents is the same as for adults.

ELAPRASE® DOSING REGIMEN

1x weekly

0.5 mg/kg of body weight

intravenous infusion over a period of **3 hours***

DOSING CALCULATION

Recommended ELAPRASE® dose:
0.5 mg per patient weight (kg)

Concentration of ELAPRASE® solution in vial:
2 mg/mL



SUPPLIES REQUIRED TO DILUTE ELAPRASE®

100 mL bag of 0.9% Sodium Chloride Injection, USP.

Low-protein-binding infusion set equipped with a low-protein-binding 0.2 micrometre (µm) in-line filter.



The calculated volume of ELAPRASE® should be withdrawn from the appropriate number of vials. Each ELAPRASE® vial contains 3 ml of concentrate. Each vial of ELAPRASE® is intended for single use only.

*The period of infusion may be gradually reduced to 1 hour if no infusion-associated reactions are observed.

C-APROM/INT/ELA/0005 May 2021